Anuncia Medical

Executive Summary

Anuncia Medical is a San Diego-based neurotherapeutic medical device company dedicated to addressing unmet needs in cerebrospinal fluid (CSF) management and neurocritical care. Its core mission is to reduce the high rate of repeat revision brain surgeries in hydrocephalus patients through noninvasive, clinically validated technologies. The lead product, the ReFlow® System, enables real-time monitoring, treatment, and prevention of shunt occlusions—a common cause of shunt failure and repeat surgeries. By offering a minimally invasive approach, the ReFlow System aims to improve patient outcomes, reduce healthcare costs, and alleviate the burden on neurosurgeons and caregivers. The hydrocephalus shunt market is large and underserved, with recurring revision surgeries representing a significant clinical and economic challenge. Anuncia’s technology has the potential to become a standard of care in shunt management, addressing a critical gap in existing treatment paradigms. With positive clinical data and a clear regulatory pathway, the company is poised for growth and adoption. As the healthcare system increasingly prioritizes value-based care and minimally invasive solutions, Anuncia Medical is well-positioned to capture market share and drive meaningful impact in neurocritical care.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for ReFlow System70% success
• Q4 2026Publication of Pivotal Clinical Study Results80% success
• H1 2027Strategic Partnership or Distribution Agreement60% success